TY - JOUR
T1 - New omics information for clinical trial utility in the primary setting
AU - Damia, Giovanna
AU - Broggini, Massimo
AU - Marsoni, Silvia
AU - Venturini, Sergio
AU - Generali, Daniele
PY - 2011/10
Y1 - 2011/10
N2 - Cancer is a complex cellular disease caused by multiple factors via genetic mutations (hereditary or somatic) or environmental factors. The emerging omics technologies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and interactomics, are increasingly being used for cancer research and personalized medicine; they have provided new opportunities in the molecular analysis of human cancer with unprecedented speed and detail. The omic approach has brought powerful ability to screen cancer cells at different levels from gene to metabolite and to search for novel drug targets, expounding the drug mechanism of action, identifying adverse effects in unexpected interaction, validating current drug targets, exploring potential applications for novel drugs, and enabling the translation from bench to bedside. As a clinical research tool, the neoadjuvant approach in breast cancer is the perfect setting for individualization of treatment based on clinical, pathological, image-guided, or molecular assessment, based on the omics techniques of tumors during treatment; neoadjuvant treatment offers the ability to discern treatment effect in vivo and may allow smaller trials targeting specific breast cancer subtypes.
AB - Cancer is a complex cellular disease caused by multiple factors via genetic mutations (hereditary or somatic) or environmental factors. The emerging omics technologies, including genomics, epigenomics, transcriptomics, proteomics, metabolomics, and interactomics, are increasingly being used for cancer research and personalized medicine; they have provided new opportunities in the molecular analysis of human cancer with unprecedented speed and detail. The omic approach has brought powerful ability to screen cancer cells at different levels from gene to metabolite and to search for novel drug targets, expounding the drug mechanism of action, identifying adverse effects in unexpected interaction, validating current drug targets, exploring potential applications for novel drugs, and enabling the translation from bench to bedside. As a clinical research tool, the neoadjuvant approach in breast cancer is the perfect setting for individualization of treatment based on clinical, pathological, image-guided, or molecular assessment, based on the omics techniques of tumors during treatment; neoadjuvant treatment offers the ability to discern treatment effect in vivo and may allow smaller trials targeting specific breast cancer subtypes.
UR - http://www.scopus.com/inward/record.url?scp=84855169009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84855169009&partnerID=8YFLogxK
U2 - 10.1093/jncimonographs/lgr032
DO - 10.1093/jncimonographs/lgr032
M3 - Article
C2 - 22043059
AN - SCOPUS:84855169009
SP - 128
EP - 133
JO - Journal of the National Cancer Institute. Monographs
JF - Journal of the National Cancer Institute. Monographs
SN - 1052-6773
IS - 43
ER -